Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sleepman who wrote (28928)	6/23/1999 6:46:00 PM
From: Henry Niman	Read Replies (3) of 32384

The DJ report on this evenings filing was very favorably written. They just focused on the positive response rate and ignored the complete remission rate. Clinical data could have been better (remission rate did not meet predefined criteria, but response rate was very good and remission rate at high dose did meet remission criteria). I suspect that Targretin will be approved, but not as an agent expected to cure the disease. The 300 mg dose will produce a response in a significant patient population, and of course the Breast cancer and psoriasis markets are much bigger than CTCL.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next